Novel strategy for Alzheimer’s disease identified

US researchers have identified an orally active compound that appears to interfere with an early step in the development of Alzheimer’s disease.

They showed that polymeric degradation products of poly [4-styrenesulfonic acid-co-maleic acid], an antibacterial compound, bind to cellular prion protein and prevent neuronal binding of oligomeric β-amyloid peptide and other early steps in the pathogenesis of dementia. In a mouse model, they found that oral administration achieved effective levels in the brain, rescuing transgenic mice from synapse loss associated with Alzheimer’s disease-like change, and memory deficits.

Web design and marketing agency Leamington Spa